microSelectron® Digital (HDR-V3) afterloader receives Shonin approval

February 13 2012  |  Press Release 

The scalable and upgradable platform with 6, 18 or 30 channels suits the needs of many brachytherapy patients and healthcare professionals  

Tokyo, February 15, 2012   
Nucletron, an Elekta company, the world's leading manufacturer of Brachytherapy solutions, announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) granted Shonin approval to market the microSelectron® Digital (HDR-V3) afterloader in Japan.

Designed for precise & targeted treatment of cancer, the microSelectron® Digital (HDR-V3) offers proven reliability in afterloading and has by far the largest installed base in the world. The scalable and upgradable platform with 6, 18 or 30 channels suits the needs of many brachytherapy patients and healthcare professionals.

Nucletron Brachytherapy Solutions tackle cancer “from the inside out” - the source of radiation is placed directly inside or next to the tumor. This precise and accurate form of radiation has proven to be a highly effective treatment option while reducing the risk of unnecessary damage to healthy tissue and organs, and thus reducing potential side effects for patients. This makes brachytherapy a complementary and valuable adjunct to any radiotherapy program.
 
Our key technological advances have resulted in an integrated package of treatment planning and delivery systems, and continue to drive efficiency, efficacy, quality and safety in brachytherapy solutions. With close to 35 years of experience, we believe that our solutions, services and extensive knowledge of precisely targeted radiotherapy can play a vital role in treating cancer successfully.

Nucletron was acquired by Elekta in September 2011.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta  aims to improve, prolong and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta reported net sales of SEK 7,904 M and EBITDA of SEK 1,744 M. Elekta employs around 2,800 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker Elekta. Website: http://www.elekta.com/